← Breakdowns
KormaDesk · AI Options Intelligence
$SLS ·SELLAS Life Sciences Group, Inc. ·Jun 30, 2026 AI Verdict: WAIT
Historical research archive
Article date: 2026-06-30. Saved snapshot timestamp: 2026-06-30T22:53:41.723533Z. Prices and conditions below are historical. Run a new analysis for current evidence.

$SLS: Strong Momentum, Wide Downside Distance

Alazar Wubet · GenghisGain
The Take

What the recorded numbers say

The receipt panel recorded $14.76, while parts of the original model text used $14.55 without a separate quote timestamp. This revision uses $14.76 consistently for its arithmetic. Compared with the $9.16 20-day average, that is a 61.1% extension. It is also 44.7% above the saved $10.20 mean analyst target. Neither calculation predicts the direction of the next session.

Momentum is evidence with limits

RSI of 85.0 described an unusually strong run in the saved series. Such strength can persist, and it can reverse abruptly. It does not identify exhausted buyers or trapped short sellers. The three WAIT votes and one CONDITIONAL vote reflected that tension, but model voting is not a calibrated probability of success.

The business question behind the ticker

For a clinical-stage company, trial results, regulatory milestones, cash requirements and financing terms can dominate a chart. A reference to ASCO 2025 is historical context, not a fresh June 2026 catalyst. A useful catalyst calendar must distinguish a company-confirmed date from an estimate or an event-count threshold. This revision makes no clinical-success forecast and imports no later trial outcome into the original setup.

A decision map rather than one magic level

The archived conditional vote required a break above $15.88. That is a prospective confirmation level, whereas the $9.16 moving average, $7.07 support and $6.93 structural floor describe increasingly distant downside references. Waiting for a move back toward an analyst target is a separate thesis. Combining those alternatives into a single “one level” instruction hid the amount of price risk involved.

What would make a revisit useful

A new review should establish the latest company announcement, the next verified milestone, available cash and any financing changes, then match the option expiry to that horizon if options are considered. The recorded $135K net flow premium and a gamma concentration near $15 do not prove forced buying or a cap on losses. Missing contract-level evidence should remain missing, not be supplied by an appealing story.

Archived council views · MIXED VIEWS
GPT
WAIT
Wanted a pullback rather than chase the extended reading.
CLAUDE
WAIT
Highlighted extension relative to the mean analyst target; original percentage was unreliable.
GEMINI
CONDITIONAL
Required confirmation above $15.88.
GROK
WAIT
Flagged the distance above the mean target and the high RSI.
Historical votes are preserved; rationales are summarized in the reviewed analysis. Model agreement and disagreement are not measured probabilities or evidence of trading performance.
Read the levels by their role
Entry confirmation, support and structural invalidation are different conditions. The analysis above identifies the relevant branches and their limits.
The recorded snapshot
Values retained from the saved KormaDesk provider snapshot. Individual vendor observation times and methodology are not available in this archive. These are not live quotes or independently reconstructed prices.
PRICE$14.76
TRENDUPTREND
RSI85.0
20D SMA$9.16
50D SMA$7.43
SUPPORT$7.07
STRUCTURAL FLOOR$6.93
ANALYST PT$10.20
P/E-61.2
GROSS MARGIN0.0%
OP MARGIN0.0%
NET FLOW PREM$135K
MAX GAMMA$15.00
VIX17.7

Sources and correction record

Editorial review: 2026-10-06. Unified price arithmetic, corrected the interpretation of the mean target, separated historical ASCO context from new catalysts, and removed squeeze and gamma certainty.

The market figures above come from the original saved article snapshot. Linked primary documents support the specific corporate facts discussed, not the historical quote or the model verdict.

No later price outcome is used to grade or improve the historical model vote. The original stored article remains preserved for audit.

Share Post to X Reddit
Alazar Wubet · GenghisGain
Founder of KormaDesk. A real options trader sharing the process, not selling picks.
Revisit this ticker with fresh evidence, or research another company.
Open KormaDesk →
KormaDesk is provided for informational and educational purposes only and is not financial advice or a recommendation to buy or sell any security. Analysis reflects model output on the data shown at a point in time and may be wrong. Do your own research. © 2026 KormaDesk.